[Gene-specific treatment approaches in Alzheimer's disease and other tauopathies]

Nervenarzt. 2020 Apr;91(4):312-317. doi: 10.1007/s00115-020-00872-6.
[Article in German]

Abstract

The pathological hallmarks of Alzheimer's disease are aggregation and accumulation of amyloid-β and tau proteins. So far most interventional studies have focused on the removal of the toxic protein products, such as antibody-based immunotherapies targeted against amyloid-β and tau proteins; however, the development of gene therapies targeting gene products involved in the disease has opened up new therapeutic strategies to reduce the development of toxic protein aggregates by inhibiting the translation of pathological Alzheimer genes using antisense oligonucleotides (ASO). This has a timely influence on development of the disease. This article gives an overview of new advances in ASO-based treatment strategies for Alzheimer's disease.

Keywords: Amyloid beta; Antibody therapy; Antisense oligonucleotides; Gene therapy; Tau.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / therapy
  • Amyloid beta-Peptides / genetics
  • Genetic Therapy* / trends
  • Humans
  • Immunotherapy / trends
  • Oligonucleotides, Antisense / therapeutic use
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • Oligonucleotides, Antisense
  • tau Proteins